American Portfolios Advisors Adverum Biotechnologies, Inc. Transaction History

American Portfolios Advisors

$2.36 Trillion
Q3 2022

A detailed history of American Portfolios Advisors transactions in Adverum Biotechnologies, Inc. stock. As of the latest transaction made, American Portfolios Advisors holds 1,150 shares of ADVM stock, worth $8,694. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,150

Holding current value

$8,694

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Mar 17, 2023	BUY	$0.96 - $9.68 $1,104 - $11,132	1,150 New	1,150 $1.09 Million
Q2 2022 Mar 20, 2023	BUY	$0.81 - $1.34 $44,550 - $73,700	55,000 Added 4782.61%	56,150 $67.4 Million
Q1 2022 Mar 21, 2023	BUY	$1.23 - $1.95 $30,750 - $48,750	25,000 Added 2173.91%	26,150 $34.3 Million
Q4 2021 Mar 21, 2023	BUY	$1.74 - $2.4 $8,700 - $12,000	5,000 Added 434.78%	6,150 $10.8 Million
Q3 2021 Mar 22, 2023	BUY	$2.08 - $3.6 $832 - $1,440	400 Added 34.78%	1,550 $3.36 Million
Q2 2021 Mar 22, 2023	BUY	$3.36 - $10.56 $1,344 - $4,224	400 Added 34.78%	1,550 $5.43 Million
Q1 2021 Mar 22, 2023	BUY	$9.26 - $14.36 $2,315 - $3,590	250 Added 21.74%	1,400 $13.8 Million
Q4 2020 Mar 22, 2023	BUY	$9.84 - $14.26 $3,936 - $5,704	400 Added 34.78%	1,550 $16.8 Million
Q3 2020 Mar 22, 2023	BUY	$10.3 - $21.64 $4,120 - $8,656	400 Added 34.78%	1,550 $16 Million
Q1 2020 Mar 24, 2023	SELL	$7.98 - $16.32 $7,581 - $15,504	-950 Reduced 82.61%	200 $1.95 Million
Q4 2019 Mar 24, 2023	SELL	$5.12 - $12.22 $4,864 - $11,609	-950 Reduced 82.61%	200 $2.3 Million
Q2 2019 Mar 24, 2023	SELL	$5.1 - $11.89 $4,845 - $11,295	-950 Reduced 82.61%	200 $2.38 Million

Others Institutions Holding ADVM

# of Institutions

Shares Held

2.53M

Call Options Held

Put Options Held

View Full List

About Adverum Biotechnologies, Inc.

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $751M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

More about ADVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.

Account

American Portfolios Advisors Adverum Biotechnologies, Inc. Transaction History